{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:28:45Z","timestamp":1778808525767,"version":"3.51.4"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":282,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["179334"],"award-info":[{"award-number":["179334"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.critrevonc.2021.103238","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T12:05:49Z","timestamp":1611749149000},"page":"103238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"159","author":[{"given":"Luca","family":"Pellegrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Andres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Suter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103238_bib0005","article-title":"Dynamics of hemorragic events and primary hemostasis deffects during treatment with ibrutinib. Real-life experience","volume":"128","author":"Acedo","year":"2016"},{"issue":"Supplement 2","key":"10.1016\/j.critrevonc.2021.103238_bib0010","first-page":"S430","article-title":"Efficacy and safety of ibrutinib in Indian patients with relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma: cases from a named patient program","volume":"32","author":"Agarwal","year":"2016","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"21","key":"10.1016\/j.critrevonc.2021.103238_bib0015","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"Supplement 3","key":"10.1016\/j.critrevonc.2021.103238_bib0020","first-page":"123","article-title":"Ibrutinib in the management of relapsed\/refractory chronic lymphocytic leukemia patients: a real-life monocentric experience","volume":"102","author":"Albi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0025","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.clml.2017.02.011","article-title":"Analysis of efficacy and tolerability of bruton tyrosine kinase inhibitor ibrutinib in various B-cell malignancies in the general community: a single-center experience","volume":"17S","author":"Ali","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0030","article-title":"A phase Ib\/II study of ibrutinib in combination with obinutuzumab-gazyva as first-line treatment for patients with chronic lymphocytic leukemia > 65 years old or with coexisting conditions","volume":"128","author":"Amaya-Chanaga","year":"2016"},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103238_bib0035","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood.V126.23.4166.4166","article-title":"Outcome of second line treatment in patients with chronic lymphocytic leukemia did not improve 2002-2013: a population-based study from a well-defined geographic region","volume":"126","author":"Asklid","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103238_bib0040","doi-asserted-by":"crossref","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103238_bib0045","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0050","article-title":"Ibrutinib in association with R-DHAP\/Ox for patients with relapsed\/refractory B-cell lymphoma: preliminary results of the biblos phase Ib lysa study","volume":"128","author":"Bonnet","year":"2016"},{"issue":"34","key":"10.1016\/j.critrevonc.2021.103238_bib0055","doi-asserted-by":"crossref","first-page":"23443","DOI":"10.18632\/oncotarget.25215","article-title":"Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed\/refractory mantle cell lymphoma","volume":"9","author":"Broccoli","year":"2018","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.critrevonc.2021.103238_bib0060","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0065","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1182\/blood-2018-99-116942","article-title":"Outcomes of ibrutinib therapy given after prior venetoclax therapy in ibrutinib-na\u00efve patients with Relapsed\/Refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"132","author":"Brown","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103238_bib0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis","volume":"184","author":"Brown","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103238_bib0075","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2021.103238_bib0080","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103238_bib0085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103238_bib0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103238_bib0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.critrevonc.2021.103238_bib0100","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103238_bib0105","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103238_bib0110","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0115","first-page":"25","article-title":"Are cardiovascular adverse events with ibrutinib well considered?","author":"Cavagna","year":"2018","journal-title":"Eur. J. Hosp. Pharm. Sci. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103238_bib0120","first-page":"481","article-title":"Safety profile of ibrutinib and idelalisib","volume":"38","author":"Charrier","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0125","article-title":"Open-label early-access programs (EAPs) for ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) or mantle-cell lymphoma (MCL)","volume":"132","author":"Chiattone","year":"2018"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0130","article-title":"Analysis of primary hemostasis alterations induced by ibrutinib assessed by shutter speed and aggregometry impedance","volume":"128","author":"Cordoba","year":"2016"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0135","article-title":"Safety and efficacy of ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood","volume":"124","author":"Coutre","year":"2014"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0140","first-page":"12","article-title":"Safety profile of the bruton\u2019s tyrosine kinase (BTK) inhibitor ibrutinib in patients with previously treated chronic lymphocytic leukemia (CLL)","volume":"1","author":"Coutre","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103238_bib0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","article-title":"Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"23","author":"Coutre","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0150","article-title":"TGR-1202 in combination with ibrutinib in patients with relapsed or refractory CLL or MCL: preliminary results of a multicenter phase I\/Ib study","volume":"128","author":"Davids","year":"2016"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0155","article-title":"Initial results of a multicenter, phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients","volume":"128","author":"Davids","year":"2016"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103238_bib0160","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2021.103238_bib0165","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103238_bib0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2021.103238_bib0175","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstrom\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10020","key":"10.1016\/j.critrevonc.2021.103238_bib0180","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0185","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.13179","article-title":"Ibrutinib-related atrial fibrillation: a single center Australian experience","author":"Ezad","year":"2019","journal-title":"Asia. J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103238_bib0190","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood.V126.23.2933.2933","article-title":"Atrial fibrillation in CLL\/SLL patients on ibrutinib","volume":"126","author":"Farooqui","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103238_bib0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.V126.23.717.717","article-title":"The importance of pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL) in routine clinical practice","volume":"126","author":"Finnes","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103238_bib0200","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103238_bib0205","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann. Math. Statist."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0210","unstructured":"GA, W. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"Supplement 3","key":"10.1016\/j.critrevonc.2021.103238_bib0215","first-page":"115","article-title":"Multicenter prospective observational study to assess efficacy and safety of ibrutinib therapy in relapsed\/refractory mantle cell lymphoma in real life (R.E.P. - Apulian hematology network)","volume":"102","author":"Gagliardi","year":"2017","journal-title":"Haematologica"},{"issue":"Supplement 2","key":"10.1016\/j.critrevonc.2021.103238_bib0220","first-page":"854","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia receiving treatment with ibruthinib","volume":"2","author":"Gendlin","year":"2018","journal-title":"HemaSphere"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0225","article-title":"Efficacy and safety of ibrutinib (IBR) after venetoclax (VEN) treatment in IBR-naive patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): follow-up of patients from the MURANO study","volume":"132","author":"Greil","year":"2018"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0230","article-title":"Incidence of atrial fibrillation and bleeding in CLL patients treated with ibrutinib: evidence from the veterans health administration","volume":"130","author":"Halwani","year":"2017"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103238_bib0235","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103238_bib0240","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2021.103238_bib0245","first-page":"727","article-title":"Platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia. Monocentric experience: clinical and laboratory characterization","volume":"101","author":"Innocenti","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0250","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0","author":"Institute","year":"2010"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103238_bib0255","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2021.103238_bib0260","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103238_bib0265","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103238_bib0270","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2016.316","article-title":"Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib","volume":"31","author":"Kazianka","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103238_bib0275","first-page":"e2701","article-title":"Management of atrial fibrillation in patients on ibrutinib: a cleveland clinic experience","volume":"10","author":"Khalid","year":"2018","journal-title":"Cureus"},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103238_bib0280","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1182\/blood.V126.23.4345.4345","article-title":"Ibrutinib in patients (PTS) with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) with relapsed disease post allogeneic stem cell transplantation (alloSCT)","volume":"126","author":"Khouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0285","article-title":"Major bleeding with ibrutinib: more than expected","volume":"128","author":"Kunk","year":"2016"},{"issue":"Supplement 2","key":"10.1016\/j.critrevonc.2021.103238_bib0290","first-page":"720","article-title":"Experience of ibrutinib in relapsed\/refractory B-cell chronic lymphocytic leukaemia and mantle cell lymphoma in a U.K. District General Hospital","volume":"102","author":"Lala","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0295","first-page":"20","article-title":"Preliminary safety results of a placebocontrolled Phase III study of ibrutinib in treatment-nayve early stage CLL patients with risk of disease progression","volume":"1","author":"Langerbeins","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103238_bib0300","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103238_bib0305","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0310","first-page":"522","article-title":"A phase 2 study of the btk inhibitor ibrutinib in genetic riskstratified relapsed and refractory patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"1","author":"Maddocks","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0315","article-title":"Safety results from the united states cohort of the ibrutinib early access treatment protocol (EAP: MCL4001) in patients with relapsed or refractory mantle cell lymphoma","volume":"124","author":"Martin","year":"2014"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103238_bib0320","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/cas.13076","article-title":"Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma","volume":"107","author":"Maruyama","year":"2016","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103238_bib0325","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0330","article-title":"Outcome of patients with re lapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and\/or 17p deletion\/TP53 mutations treated with ibrutinib according to a named patient program (NPP) in Italy: preliminary analysis of a real life retrospective study","volume":"128","author":"Mauro","year":"2016"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2021.103238_bib0335","first-page":"228","article-title":"Ibrutinib for relapsed CLL patients older than 75 years: proven efficacy, toxicities to know","volume":"101","author":"Michallet","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0340","volume":"130","author":"Michallet","year":"2017"},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103238_bib0345","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103238_bib0350","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"Supplement 3","key":"10.1016\/j.critrevonc.2021.103238_bib0355","first-page":"49","article-title":"Effectiveness and safety of ibrutinib in relapsed\/refractory mantle cell lymphoma treated in Italy according to the ibrutinib named patient program: the real life results","volume":"102","author":"Morigi","year":"2017","journal-title":"Haematologica"},{"issue":"Supplement 2","key":"10.1016\/j.critrevonc.2021.103238_bib0360","first-page":"423","article-title":"Platelet function assays for stratification of bleeding risks in CLL patients on Ibrutinib treatment","volume":"102","author":"Nikitin","year":"2017","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.critrevonc.2021.103238_bib0365","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103238_bib0370","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2021.103238_bib0375","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103238_bib0380","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.V126.23.2935.2935","article-title":"Ibrutinib therapy for chronic lymphocytic leukemia (CLL): an analysis of a large cohort of patients treated in routine clinical practice","volume":"126","author":"Parikh","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103238_bib0385","article-title":"Major bleeding complications among patients treated with ibrutinib and concomitant antiplatelet, anticoagulant, or supplemental therapy","volume":"128","author":"Pavlik","year":"2016"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103238_bib0390","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-018-0626-0","article-title":"Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study","volume":"11","author":"Reda","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103238_bib0395","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.critrevonc.2021.103238_bib0400","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood.V126.23.2945.2945","article-title":"Outcomes of patients with relapsed\/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience","volume":"126","author":"Sandoval-Sus","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103238_bib0405","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103238_bib0410","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 2","key":"10.1016\/j.critrevonc.2021.103238_bib0415","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/hon.2439_146","article-title":"Portuguese real-life experience with ibrutinib outside clinical trials - A multicenter analysis","volume":"35","author":"Silva","year":"2017","journal-title":"Hematol. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2021.103238_bib0420","first-page":"139","article-title":"Studies on platelet function in a group of cll and MCL patients treated with ibrutinib-preliminary results","volume":"101","author":"Sokolowska","year":"2016","journal-title":"Haematologica"},{"issue":"Supplement 2","key":"10.1016\/j.critrevonc.2021.103238_bib0425","first-page":"652","article-title":"Studies on platelet function in a group of cll patients during the first year of ibrutinib treatment","volume":"2","author":"Sokolowska","year":"2018","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103238_bib0430","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103238_bib0435","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2021.103238_bib0440","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0445","article-title":"Prolonged improvement in patient-reported outcomes (PROs) and well-being in older patients with treatment-naive (TN) chronic lymphocytic leukemia treated with ibrutinib (ibr): 3-year follow-up of the RESONATE-2 study","volume":"130","author":"Tedeschi","year":"2017"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103238_bib0450","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12185-018-02577-8","article-title":"Ibrutinib in Japanese patients with relapsed\/refractory B-cell malignancies: final analysis of phase I study","volume":"109","author":"Tobinai","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"15","key":"10.1016\/j.critrevonc.2021.103238_bib0455","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0460","article-title":"Ibrutinib is highly active as first line therapy in symptomatic waldenstrom\u2019s macroglobulinemia","volume":"130","author":"Treon","year":"2017"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2021.103238_bib0465","first-page":"86","article-title":"Real world experience of ibrutinib in mantle cell lymphoma-prospective multi-centre data from 61 patients treated for MCL with ibrutinib (single agent) via the expanded access programme in Great Britain andireland","volume":"173","author":"Tucker","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"Supplement 2","key":"10.1016\/j.critrevonc.2021.103238_bib0470","first-page":"858","article-title":"Safety profile of ibrutinib: a retrospective analysis of 31 patients","volume":"2","author":"Uriarte","year":"2018","journal-title":"HemaSphere"},{"issue":"21","key":"10.1016\/j.critrevonc.2021.103238_bib0475","article-title":"Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103238_bib0480","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.critrevonc.2021.103238_bib0485","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0490","article-title":"Real-world results on ibrutinib in relapsed\/refractory CLL: a 21-month follow-up of 95 swedish patients treated in a compassionate use program","volume":"130","author":"Winqvist","year":"2017"},{"issue":"26","key":"10.1016\/j.critrevonc.2021.103238_bib0495","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103238_bib0500","article-title":"Elucidation of mild bleeding disorders reported under ibrutinib (imbruvica(R)) therapy: implications for optimal clinical management","volume":"124","author":"Ysebaert","year":"2014"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103238_bib0505","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1002\/ajh.24773","article-title":"Real-world results of ibrutinib in relapsed\/refractory CLL in France: early results on a large series of 428 patients","volume":"92","author":"Ysebaert","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103238_bib0510","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","article-title":"Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials","volume":"17","author":"Yun","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:36:11Z","timestamp":1760902571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":102,"alternative-id":["S1040842821000263"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103238","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103238"}}